Nuformix - Solid Form Discovery
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing
News - Nuformix
Jan 31, 2022 · Nuformix plc (LSE:NFX) (“Nuformix” or “the Company”), the pharmaceutical development… 27th May 2020. Business Update. Nuformix, the pharmaceutical development …
Company - Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing
Investors - Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing
NXP002 (inhaled tranilast) for IPF -preclinical - Nuformix
NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.Tranilast …
Overview - Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing
News and Media - Nuformix
Latest news and media from Nuformix. RNS News . Videos and Audios
notice of this AGM, please visit our company website https://www.nuformix.com/. We appreciate your ongoing support and trust in Nuformix plc. We remain committed to maintaining …
- [PDF]
Nuformix plc
Nuformix plc (“Nuformix” or the “Company”) and its subsidiary (together the “Group”) is a pharmaceutical development group targeting unmet medical needs in fibrosis and oncology via …
Executive leadership and Board - Nuformix
Dr Dan Gooding was a co-founder of Nuformix and the Company’s CEO until June 2020. He was reappointed as an Executive Director in July 2022.